McKesson Corporation
30-Second Executive Brief
Executive Assessment
McKesson Corporation functions as an established institution within Healthcare & Life Sciences, backed by 55% sourcing coverage, though its relative influence is cooling.
- Maintains 2 mapped relationships across the graph
- 55% sourcing coverage across sourced relationships
- Tracked as established institution within the Healthcare & Life Sciences category
Executive Snapshot
- Strategic Role
- Established Institution
- Sourcing Coverage
- 55%
- Ecosystem Influence
- High
- Strategic Momentum
- Decelerating
View Methodology →
Computed live from this entity's own relationships and evidence: how many relationships carry at least one linked citation, weighted with citation recency and source type — independent of Strategic Importance, and not a prediction. Not a hand-typed number; recalculated on every read.
Coverage
- Mapped Relationships
- 2
- Technology Domains
- 3
Strategic Implications
- Central node connecting multiple strategic ecosystems
- Directly influences technology and capital flows
- Material relevance to downstream dependency mapping
Top Opportunities
Top Risks
Critical Dependencies
Major US pharmaceutical distribution and healthcare services company; reported fiscal year 2026 (ended March 2026) consolidated revenues of $403.4 billion (up 12% year-over-year) and adjusted EPS of $39.11 (up 18%), announcing plans to separate its Medical-Surgical Solutions business.
Leading Indicators
Hiring and patent filing trends — the underlying numbers Momentum is computed from. Insider filing activity is tracked separately under Sources below.
Additional Intelligence Signals
Patent citation lineage, earnings-call mentions, and federal contract disclosures — automatically collected, not yet visible anywhere else on the site.
Federal contract disclosures
Department of Veterans Affairs — $1,406,868,182: EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 NOVEMBER
USAspending.gov · Nov 1, 2025
Department of Veterans Affairs — $1,398,025,092: EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 MAY
USAspending.gov · May 1, 2026
Department of Veterans Affairs — $1,191,973,258: EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 JUNE
USAspending.gov · Jun 1, 2026
Department of Veterans Affairs — $1,191,348,081: EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 APRIL
USAspending.gov · Apr 1, 2026
Department of Veterans Affairs — $1,184,200,532: EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 OCTOBER
USAspending.gov · Oct 1, 2025
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
1 source
- McKesson — McKesson Reports Fiscal 2026 Fourth Quarter and Full Year Results, Provides Fiscal 2027 Guidance, and Reaffirms Long-Term Financial Growth Targetscompany
Latest Activity
Insider Filing Activity
Counts filing frequency only — transaction direction/size wasn't parseable from the sampled filings · sourced from SEC EDGAR · as of Sep 7, 2026
Acquisition & Investment Fit
AI-reasoned, generated only from entities already in InsightNodes's own graph — a hypothetical strategic-fit exercise, not real M&A intelligence or a signal that any deal is planned or in progress.
Relationship Map
The relationships surrounding McKesson Corporation — ownership, dependencies, regulation, technology and market context. Click any node to make it the new center, 2 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far (last 6 months)
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
McKesson Corporation's Timeline
A sourced, dated history of McKesson Corporation's key moments — founding to present.
May 2026 · FY2026 revenue rises 12% to $403.4 billion; plans Medical-Surgical Solutions separation
McKesson reported FY2026 consolidated revenues of $403.4 billion, up 12% year-over-year, with adjusted EPS of $39.11, up 18% and above previously communicated long-range growth targets, while announcing its intent to separate its Medical-Surgical Solutions business.